Design Therapeutics, Inc. (DSGN) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 16 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026after close 35 8-K
Q2 FY2026Mon, Aug 3, 2026before open 34 8-K
Q1 FY2026Tue, Apr 28, 2026after close 28 8-K
Q4 FY2025Mon, Mar 9, 2026after close 68 8-K
Q3 FY2025Wed, Nov 5, 2025after close 36 8-K
Q2 FY2025Thu, Aug 7, 2025after close 38 8-K
Q1 FY2025Wed, May 7, 2025after close 37 8-K
Q4 FY2024Mon, Mar 10, 2025before open 69 8-K

What they guided beta

Q3 FY2026 "Clinical readouts expected in 2027 will help guide these programs as we pursue our vision for the GeneTAC ® platform: to address the underlying causes of serious genetic diseases and deliver meaningful benefits for patients.”" exhibit
Q3 FY2026 "Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027." exhibit
Q3 FY2026 "Design anticipates reporting data from this trial in 2027." exhibit
Q3 FY2026 "Fuchs Endothelial Corneal Dystrophy (FECD): A Phase 2 biomarker trial of DT-168 is ongoing to evaluate safety, tolerability and corneal endothelium biomarkers in FECD patients who are scheduled for corneal transplant surgery, with data expected in 2027." exhibit
Q2 FY2026 "Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1" exhibit
Q2 FY2026 "Next Steps and Expected Milestones: Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027." exhibit
Q2 FY2026 "Design anticipates reporting data from this study in 2027." exhibit
Q2 FY2026 "Data is now expected in 2027 due to a delay in the anticipated supply of DT-168 blow-fill-seal eye droppers." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/DSGN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/DSGN

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

DSGN earnings date badge

HTML

<a href="https://veritasdata.dev/company/DSGN/"><img src="https://veritasdata.dev/embed/DSGN.svg" alt="DSGN earnings date" width="240" height="56"></a>

Markdown

[![DSGN earnings date](https://veritasdata.dev/embed/DSGN.svg)](https://veritasdata.dev/company/DSGN/)

Script

<script async src="https://veritasdata.dev/embed/DSGN.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/DSGN"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.